# ARVN catalysts: ARVINAS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/arvn/catalysts

> ARVINAS, INC. (ARVN) has 2 upcoming catalysts. The next is the ARV-027 interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ARVN?

ARVINAS, INC. (ARVN) has 2 upcoming catalysts. The next is the ARV-027 interim data readout, 1H 2027. SEC Form 10-Q: "We plan to continue enrollment in the multiple ascending dose cohorts of the Phase 1 clinical trial of ARV-027 in healthy volunteers and share initial data evaluating AR-degradation in muscle in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/arvn/catalysts)

Source: SEC Form 10-Q, accession 0001628280-26-069464, https://www.sec.gov/Archives/edgar/data/1655759/000162828026069464/arvn-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/companies/arvn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ARVINAS, INC. |
| Ticker | ARVN (Nasdaq) |
| SEC CIK | 1655759 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/arvn |

## Cash runway

Cash $558.4M as of 2026-09-30; quarterly burn $10.4M; about 161.1 months of runway at that rate (XBRL company facts, accession 0001628280-26-069464).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 2025 | [ARV-102 trial start](https://sec-api.dev/pdufa/arv-102) | ARVN | PD and initiate the MAD portion of the Phase 1 clinical trial in patients with PD in 2025 | scheduled | "We plan to complete enrollment and present initial data from the ongoing SAD Phase 1 clinical trial of ARV-102 in patients with PD and initiate the MAD portion of the Phase 1 clinical trial in patients with PD in 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/arvn-20241231.htm)) |
| Q1 2025 | [VEPPANU (vepdegestrant) topline data readout](https://sec-api.dev/pdufa/vepdegestrant) | ARVN |  | scheduled | "Based on current trial status, which completed enrollment in the fourth quarter of 2024, the primary completion date for this clinical trial has been reprojected from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/arvn-20241118.htm)) |
| January 10, 2025 | [ARV-102 trial start](https://sec-api.dev/pdufa/arv-102) | ARVN | Parkinson's disease | completed | "The Company also announced that it recently initiated a Phase 1 clinical trial with PROTAC leucine-rich repeat kinase 2 ("LRRK2") protein degrader ARV-102 in patients with Parkinson's disease and that, in 2025, the Company plans to:" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm)) |
| February 11, 2025 | [ARV-102 trial start](https://sec-api.dev/pdufa/arv-102) | ARVN | Parkinson's disease | completed | "- Initiated a Phase 1 trial with ARV-102 in patients with Parkinson's disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer's Disease/Parkinson's Disease congress -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211xexx991.htm)) |
| February 11, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211xexx991.htm)) |
| March 11, 2025 | [VEPPANU (vepdegestrant) topline data readout](https://sec-api.dev/pdufa/vepdegestrant) | ARVN |  | completed, negative | "On March 11, 2025, Arvinas, Inc. (the "Company"), along with Pfizer, Inc. ("Pfizer"), announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive ("ER+"), human epidermal growth factor receptor 2-negative ("HER2-") ("ER+/HER2-") advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase ("CDK") 4/6 inhibitors and endocrine therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/arvn-20250311.htm)) |
| April 30, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250331xexx991.htm)) |
| 2H 2025 | [ARV-806 trial start](https://sec-api.dev/pdufa/arv-806) | ARVN | solid tumors harboring KRAS G12D mutations | scheduled | "We expect to initiate a first-in-human Phase 1 clinical trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000085/arvn-20250331.htm)) |
| 2H 2025 | [ARV-102 interim data readout](https://sec-api.dev/pdufa/arv-102) | ARVN |  | scheduled | "We expect to share initial data from this SAD cohort of the Phase 1 clinical trial in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm)) |
| July 15, 2025 | [ARVINAS, INC. PDUFA date](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm)) |
| August 6, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/arvn-20250630xexx991.htm)) |
| August 8, 2025 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | with estrogen receptor positive | completed | "On August 8, 2025, the Company issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted a new drug application ("NDA") for vepdegestrant for the treatment of patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative ("HER2-") ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000141/arvn-20250808.htm)) |
| November 5, 2025 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | estrogen receptor 1 | completed | "•Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for vepdegestrant for the treatment of estrogen receptor 1 (ESR1) mutated, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine-based therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm)) |
| November 5, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm)) |
| 2026 | [ARV-102 interim data readout](https://sec-api.dev/pdufa/arv-102) | ARVN | Parkinson's disease | scheduled | "The Company plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease (ARV-102-103) in 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm)) |
| 2026 | [ARV-027 trial start](https://sec-api.dev/pdufa/arv-027) | ARVN |  | scheduled | "Arvinas plans to initiate a first-in-human Phase 1 clinical trial of ARV-027 in healthy volunteers, pending regulatory feedback, in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/q32025earningsrelease.htm)) |
| 2026 | [ARV-393 trial start](https://sec-api.dev/pdufa/arv-393) | ARVN | DLBCL in 2026 | scheduled | ""The initiation of our Phase 1 combination clinical trial, planned for 2026, represents an important step toward defining the potential of ARV-393 in the treatment of this aggressive form of lymphoma."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/arvn-ashxpressxreleasexf.htm)) |
| February 24, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026010865/q42025earningsrelease.htm)) |
| Q2 2026 | [ARV-102 trial start](https://sec-api.dev/pdufa/arv-102) | ARVN | progressive supranuclear palsy | scheduled | "Pending regulatory feedback, the Company intends to initiate a Phase 1b clinical trial in progressive supranuclear palsy in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while it continues to evaluate development options for ARV-102 in Parkinson's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm)) |
| May 12, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/q12026earningsrelease.htm)) |
| May 12, 2026 | [VEPPANU (vepdegestrant) FDA approval](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | ESR1m, ER+/HER2- advanced breast cancer - | completed, approved | "- Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/q12026earningsrelease.htm)) |
| June 5, 2026 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN |  | completed | "In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA action date of June 5, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069464/arvn-20260930.htm)) |
| June 5, 2026 | [VEPPANU (vepdegestrant) PDUFA date](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | with estrogen receptor-positive | completed, approved | "Vepdegestrant was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvnstrategicupdaterelea.htm)) |
| June 5, 2026 | [IBRANCE® (palbociclib) PDUFA date](https://sec-api.dev/pdufa/palbociclib) | ARVN |  | completed, approved | "•Footnotes included in the graphic above: (a) Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, and relapsed/refractory mature B cell NHL; (b) PDUFA date of June 5, 2026; and (c) Phase 1/2 combination clinical trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm)) |
| Q3 2026 | [ARV-6723 trial start](https://sec-api.dev/pdufa/arv-6723) | ARVN | advanced solid tumors | scheduled | "Arvinas plans to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm)) |
| 2H 2026 | [ARVINAS, INC. interim data readout](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | scheduled | "◦Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm)) |
| August 4, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm)) |
| November 3, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069101/q32026earningsrelease.htm)) |
| 1H 2027 | [ARV-027 interim data readout](https://sec-api.dev/pdufa/arv-027) | ARVN | SBMA Initial data | scheduled | "We plan to continue enrollment in the multiple ascending dose cohorts of the Phase 1 clinical trial of ARV-027 in healthy volunteers and share initial data evaluating AR-degradation in muscle in the first half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069464/arvn-20260930.htm)) |
| mid-2027 | [ARV-393 interim data readout](https://sec-api.dev/pdufa/arv-393) | ARVN | DLBCL in mid-2027 | scheduled | "Enrollment in this clinical trial is currently ongoing, and we plan to share initial data from this combination cohort of ARV-393 with glofitamab in patients with DLBCL in mid-2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069464/arvn-20260930.htm)) |

## Drugs

- [ARV-027](https://sec-api.dev/pdufa/arv-027): sbma initial data
- [ARV-102](https://sec-api.dev/pdufa/arv-102): parkinson's disease, progressive supranuclear palsy, pd and initiate the mad portion of the phase 1 clinical trial in patients with pd in 2025, pd in 2026
- [ARV-393](https://sec-api.dev/pdufa/arv-393): dlbcl in mid-2027, dlbcl in 2026
- [ARV-6723](https://sec-api.dev/pdufa/arv-6723): advanced solid tumors, advanced solid tumors in mid-2026, advanced solid tumors in 2026, advanced solid tumors in q3 2026
- [ARV-806](https://sec-api.dev/pdufa/arv-806): solid tumors harboring kras g12d mutations
- [VEPPANU (vepdegestrant)](https://sec-api.dev/pdufa/vepdegestrant): with estrogen receptor-positive, with er+/her2-, esr1-mutated advanced or metastatic breast cancer, esr1m, er+/her2- advanced breast cancer -, estrogen receptor 1, with estrogen receptor positive, with er+/her2- esr1-mutated advanced or metastatic breast cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/arvn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARVN catalysts: ARVINAS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/arvn/catalysts

```bibtex
@misc{secapidev_companies_arvn_catalysts_20261116,
  title        = {ARVN catalysts: ARVINAS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/arvn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_arvn_catalysts_20261116","title":"ARVN catalysts: ARVINAS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/arvn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
